SNYNF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat DBV Technologies SA's return on equity of --.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.82%. On the other hand DBV Technologies SA has an analysts' consensus of $15.52 which suggests that it could grow by 63.35%. Given that DBV Technologies SA has higher upside potential than Sanofi SA, analysts believe DBV Technologies SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.59%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than DBV Technologies SA quarterly revenues of --. Sanofi SA's net income of $2B is higher than DBV Technologies SA's net income of -$27.1M. Notably, Sanofi SA's price-to-earnings ratio is 18.46x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.66x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Genfit SA's return on equity of --.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.82%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 147.78%. Given that Genfit SA has higher upside potential than Sanofi SA, analysts believe Genfit SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.59%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Genfit SA quarterly revenues of --. Sanofi SA's net income of $2B is higher than Genfit SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 18.46x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.66x versus 2.95x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Innate Pharma SA's return on equity of -72.79%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 23.82%. On the other hand Innate Pharma SA has an analysts' consensus of $7.84 which suggests that it could grow by 229.92%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.329%.

Sanofi SA has a quarterly dividend of $4.05 per share corresponding to a yield of 7.59%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Innate Pharma SA quarterly revenues of --. Sanofi SA's net income of $2B is higher than Innate Pharma SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 18.46x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.66x versus 14.22x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.